FDA approves first-in-class drug for hypertension
Mineralys Therapeutics has secured a landmark U.S. Food and Drug Administration approval for Lorundrostat, establishing the first new mechanistic class for hypertension in over a decade and targeting patients whose blood pressure remains high despite existing treatments (https://www.nature.com/articles/d41573-026-00085-7). This approval validates the aldosterone synthase inhibition pathway. A new tool arrives for a persistent clinical problem.
Drug Profile
Lorundrostat is an oral, small-molecule inhibitor of aldosterone synthase (also known as CYP11B2). By selectively blocking this terminal enzyme in the mineralocorticoid synthesis pathway, the drug directly reduces the production of aldosterone. Aldosterone is a primary driver of sodium and water retention, and its overproduction is a known factor in difficult-to-treat hypertension.
The drug’s class is Aldosterone Synthase Inhibitor (ASI). What makes Lorundrostat structurally and functionally distinct from older agents like spironolactone is its mechanism. Instead of blocking the mineralocorticoid receptor (MR), which can lead to off-target hormonal effects, Lorundrostat acts upstream to prevent the creation of the ligand itself. Its high selectivity for CYP11B2 over the structurally similar CYP11B1 enzyme (responsible for cortisol synthesis) is a key design feature intended to minimize disruption of the hypothalamic-pituitary-adrenal axis (https://www.nature.com/articles/d41573-026-00085-7).
Clinical Data
The approval was supported by data from the ADVANCE-HTN study, a Phase 3, randomized, double-blind, placebo-controlled trial. The study enrolled adults with uncontrolled hypertension who were already on at least two background antihypertensive medications.
| Endpoint | Lorundrostat Result | Placebo Result | Trial | | ------------------------------------------------------ | ------------------- | -------------- | ------------- | | Change in Systolic Blood Pressure (AOSBP) at Week 12 | -14.1 mmHg | -4.9 mmHg | ADVANCE-HTN | | % Patients Achieving BP Control (<130/80 mmHg) | 42% | 18% | ADVANCE-HTN | | Change in 24-hr Ambulatory SBP at Week 12 | -11.8 mmHg | -3.7 mmHg | ADVANCE-HTN |
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Regulatory Body | Status | |
| FDA (United States) | ✓ Approved May 22, 2026 | |
| EMA (Europe) | No submission entry detected in BrunoSan DB as of May 22, 2026. | |
| Health Canada | No submission entry detected in BrunoSan DB as of May 22, 2026. | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB as of May 22, 2026. |
STATUS
Market Impact
The hypertension market is a vast, commoditized space dominated by low-cost generic angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, and diuretics. Lorundrostat is not positioned to compete as a first-line agent. Its commercial viability depends on its adoption within the substantial niche of resistant or uncontrolled hypertension—patients who fail to reach blood pressure goals despite treatment with three or more agents. In this segment, it will compete primarily with the off-patent mineralocorticoid receptor antagonist spironolactone, which is effective but limited by a side-effect profile that includes gynecomastia and hyperkalemia.
Lorundrostat's primary commercial lever will be its differentiated safety profile. If it can demonstrate fewer hormonal side effects, it could capture patients intolerant to or unwilling to take spironolactone. Payer negotiations will be a critical hurdle. Mineralys must provide strong health economic data to justify a premium price over a generic that costs pennies per day. The approval also serves as a major validation for the entire ASI class, likely intensifying development efforts from competitors with similar assets, such as AstraZeneca's Baxdrostat. This first approval sets the regulatory and commercial benchmark for all subsequent ASIs.
Based on BrunoSan pipeline data tracking 14,750 global regulatory events, first-in-class approvals in high-prevalence indications like hypertension face a distinct post-approval trajectory. While the FDA approval is a major de-risking event, our data on 2,197 EMA entries shows that European regulators often require cardiovascular outcomes data for novel antihypertensives, suggesting a potential request for a post-marketing study. Lorundrostat's U.S. launch success will hinge on physician education for this new mechanism, as our tracking of 126 FDA actions today alone shows the high volume of information clinicians must process. The lack of concurrent ex-U.S. filings is typical for a company of Mineralys' size, but it creates a window for larger competitors to advance their own ASI programs in Europe and other markets.